Nicholas Investment Partners LP Reduces Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Nicholas Investment Partners LP lowered its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 37.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 177,382 shares of the biotechnology company’s stock after selling 106,314 shares during the quarter. Nicholas Investment Partners LP’s holdings in ADMA Biologics were worth $3,042,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after acquiring an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after purchasing an additional 700 shares during the period. Summit Investment Advisors Inc. boosted its holdings in ADMA Biologics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 746 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in ADMA Biologics by 2.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 751 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its holdings in shares of ADMA Biologics by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock valued at $1,365,000 after acquiring an additional 897 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th. Raymond James upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. Finally, StockNews.com downgraded shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.

ADMA Biologics Stock Down 2.8%

Shares of NASDAQ ADMA opened at $19.88 on Wednesday. The business has a 50-day moving average price of $20.28 and a 200 day moving average price of $18.79. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.72 billion, a PE ratio of 71.00 and a beta of 0.57. ADMA Biologics, Inc. has a 52-week low of $8.75 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $114.80 million during the quarter, compared to analysts’ expectations of $116.40 million. During the same period last year, the business posted $0.08 earnings per share. The company’s quarterly revenue was up 40.2% on a year-over-year basis. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.